Consumers and Providers Face Biosimilar Knowledge Hurdles

July 07, 2025

Significant knowledge gaps about biosimilars persist among consumers and healthcare professionals, hindering their adoption and potential benefits in health care.

Australian Patients With IBD Switched to Biosimilar Infliximab Maintain Long-Term Persistence

July 05, 2025

The Top 5 Biosimilar Articles for the Week of June 30

July 04, 2025

Biosimilar SB12 Matches Eculizumab in PNH Treatment Across Diverse Patient Groups

July 03, 2025

Biosimilars Rheumatology Roundup: June 2025

July 01, 2025

The Top 5 Biosimilar Articles for the Week of February 12

February 16th 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of February 12, 2024.

Report: Policy Changes Needed to Ensure Long-Term Market Stability for Biosimilars

February 15th 2024

By Skylar Jeremias

Article

The report stresses the need to tackle issues like misaligned rebates, slow uptake, and market viability to sustain biosimilars' benefits for health care, highlighting challenges in reimbursement and suggesting policy changes for a stable environment.

Patient With MS Sues J&J Over ERISA Violation

February 14th 2024

By Skylar Jeremias

Article

After a patient with multiple sclerosis (MS) was forced to pay exorbitant out-of-pocket costs for a brand name medication when she could’ve gotten a generic for way less, the patient filed a class action complaint against her employer, Johnson & Johnson (J&J), for violating the Employee Retirement Income Security Act of 1974 (ERISA).

Biosimilar Candidate CT-P43 Shows Biosimilarity With Ustekinumab Originator in Plaque Psoriasis

February 13th 2024

By Cameron Santoro

Article

Similar efficacy, safety, pharmacokinetics, and immunogenicity were found when comparing Stelara, originator ustekinumab, and CT-P43, an ustekinumab biosimilar candidate, in patients with moderate to severe plaque psoriasis.

Eye on Pharma: Celltrion Biosimilars Win Tenders; Oral Ustekinumab Device Passes Phase 1 Trial

February 12th 2024

By Skylar Jeremias

Article

Celltrion announced that 3 of its oncology biosimilar products have won tender contracts in France and Italy, and an experimental oral delivery device utilizing an ustekinumab biosimilar was successful in a phase 1 study.

Navigating the Biosimilar Patent Landscape With Ha Kung Wong

February 11th 2024

By Cameron Santoro

Video

In an interview with Ha Kung Wong, JD, he addresses the patent legal system biosimilars are required to undergo and how this helps resolve patent disputes early in the development process.

Analyzing Safety of Switching From Originators to Biosimilars: A Meta-Analysis of 21 Trials

February 10th 2024

By Deana Ferreri, PhD

Article

The authors of a meta-analysis assessing several disease states found no significant differences in serious adverse events, deaths, or treatment discontinuations between patients who switched from reference products to biosimilars and those who did not.

Quiz: How Well Do You Know These Biosimilar Policy Essentials?

February 9th 2024

By The Center for Biosimilars Staff

Article

Test your knowledge of major biosimilar policies, including challenging regulatory frameworks from around the world.

The Top 5 Biosimilar Articles for the Week of February 5

February 9th 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of February 5, 2024.

The Hatch-Waxman Act Turns 40: The Law That Made Biosimilars Possible

February 8th 2024

By Skylar Jeremias

Article

To mark the 40th anniversary of the Hatch-Waxman Act, the Association for Accessible Medicines published a white paper outlining the benefits and challenges associated with the landmark policy as well as solutions to ensure a stable pharmaceutical industry for the future.